Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results.

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 billion, a 22% increase year over year. Comirnaty revenue declined by 37% ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Pfizer (PFE) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.10 per share a year ago. These figures ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and sending the stock up about 1% in premarket trading.

Baby boomers looking to set up their portfolios for a relaxing and rewarding retirement have plenty of factors to consider.

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...